The global AI in diagnostics market, valued at USD 1.5 billion in 2024, is projected to surge to USD 16.89 billion by 2035, a staggering 24.1% annual growth. This expansion, driven by a wave of new FDA-cleared devices and specific product innovations, signals profound financial opportunities over the next decade, according to Rootsanalysis and Precedence Research.
However, despite this explosive growth and regulatory acceleration, widespread, equitable integration of AI into clinical practice and its full economic and patient impact remain nascent. Immediate benefits and commercialization are concentrated, not universally distributed.
Therefore, companies strategically investing in AI-driven diagnostic platforms and navigating regulatory pathways effectively are poised to capture significant market share, potentially reshaping healthcare delivery over the next decade. This concentration implies a segmented, rather than universal, impact on global healthcare access and cost structures.
Current Market Landscape and Immediate Trajectory
The AI in diagnostics market grew from USD 606.2 million in 2021 to USD 1.1 billion in 2023, showing consistent year-over-year expansion. Projections place the market at USD 1.8 billion in 2025, according to Gminsights and Rootsanalysis. North America is set to dominate with a 50.84% market share in 2025, per Precedence Research and Fortune Business Insights.
The established momentum and current geographical concentration of AI diagnostic adoption are evident in these figures. North America's overwhelming market share reveals that immediate commercialization benefits are heavily concentrated in developed markets, leaving vast segments of the global population underserved by these advancements.
Regulatory Acceleration and Technological Drivers
The FDA cleared 171 AI-enabled medical devices in 2023, with neurology and radiology emerging as significant segments, according to EIN Presswire. Regulatory acceleration provides a clear pathway for new AI diagnostic tools, particularly as the software segment commands the highest market share at 55%, per Rootsanalysis. The dominance of the software segment underscores a strategic pivot towards digital solutions, where innovation in algorithms and data processing, rather than solely hardware, drives market entry and expansion as regulatory hurdles diminish.
The shift towards scalable data processing and analytical services is particularly evident in veterinary diagnostics. The cloud-native PIMS platform experienced double-digit growth in its installed base in Q1 2026, with virtually all new placements being cloud-based, according to Kavout | AI. The future of AI diagnostics hinges on scalable, data-driven software solutions, compelling traditional medical device manufacturers to rapidly pivot towards service-oriented models or risk obsolescence, as suggested by the dominance of software and cloud-native deployments.
Real-World Innovation and Long-Term Outlook
IDEXX placed over 1,900 inVue Dx instruments in Q4 2025, fueling a 12% year-over-year expansion of its global premium instrument installed base, Kavout | AI reported. The placement of over 1,900 inVue Dx instruments by IDEXX in Q4 2025 marks tangible success for AI-powered diagnostic instruments in the animal health sector, demonstrating how specialized, vertically integrated solutions can achieve rapid adoption. The strategic expansion of the IDEXX Cancer Dx panel to include canine mast cell tumor detection mid-year 2026 in North America further solidifies targeted AI application and market penetration within specific veterinary segments.
While Gminsights projects the AI in diagnostics market to reach USD 10.5 billion by 2034, Rootsanalysis and Precedence Research anticipate a higher market value of USD 16.89 billion by 2035. Persistent uncertainty regarding widespread clinical integration and the true economic impact of AI in diagnostics is underscored by this discrepancy in long-term projections. It suggests that regulatory speed does not automatically translate to immediate, universal adoption or cost savings.
The AI in diagnostics market, while poised for significant expansion driven by regulatory advancements and software innovation, will likely see its ultimate impact shaped by the ability of companies to bridge the gap between technological capability and equitable, widespread clinical integration.
